Retrospective Cohort Study
Copyright ©The Author(s) 2019.
World J Cardiol. Jan 26, 2019; 11(1): 24-37
Published online Jan 26, 2019. doi: 10.4330/wjc.v11.i1.24
Table 1 Baseline characteristics
n = 226No plaque, n = 150Plaque, n = 76P value
Age63.2 (11.4)60.6 (12.1)68.2 (7.3)< 0.001a
Male sex106 (46.9%)64 (42.7%)42 (55.3%)0.099
Hypertension166 (73.5%)100 (66.7%)66 (86.8%)0.002a
Diabetes mellitus45 (19.9%)24 (16.0%)21 (27.6%)0.058
Dyslipidaemia124 (54.9%)74 (49.3%)50 (65.8%)0.027a
Current smoker55 (24.3%)36 (24.0%)19 (25.0%)0.999
Family history of premature CAD17 (7.5%)13 (8.7%)4 (5.3%)0.516
BMI, kg/m233.3 (4.1)33.2 (4.5)33.4 (3.0)0.694
Obesity0.033a
Grade 1179 (79.2%)126 (84.0%)53 (69.7%)
Grade 239 (17.3%)19 (12.7%)20 (26.3%)
Grade 38 (3.5%)5 (3.3%)3 (3.9%)
No cardiovascular risk factors29 (12.8%)28 (18.7%)1 (1.3%)< 0.001a
SCORE< 0.001a
Low-risk, < 1%29 (12.8%)28 (18.7%)1 (1.3%)
Moderate-risk, 1%-5%113 (50.0%)78 (52.0%)35 (46.1%)
High risk, 5%-10%33 (14.6%)20 (13.3%)13 (17.1%)
Very high-risk, ≥ 10%49 (21.7%)24 (16.0%)25 (32.9%)
Not classifiable2 (0.9%)02 (2.6%)
CAD PTP0.017a
< 15%10 (4.4%)10 (6.7%)0
15-65%180 (79.6%)121 (80.7%)59 (77.6%)
65-85%36 (15.9%)19 (12.7%)17 (22.4%)
> 85%0 (0%)0 (0%)0 (0%)
Fasting plasma glucose, mg/dL113.8 (32.2)112.5 (33.4)116.6 (29.5)0.369
Glomerular filtration rate, mL/min/1.73 m287.6 (25.4)91.4 (27.1)79.7 (20.3)< 0.001a
Total cholesterol, mg/dL199.6 (40.5)196.9 (38.5)205.0 (43.9)0.159
HDL cholesterol, mg/dL48.6 (12.3)49.6 (13.4)46.5 (9.1)0.043a
Triglycerides, mg/dL143.6 (75.9)133.0 (60.0)164.8 (97.6)0.011a
LDL cholesterol, mg/dL122.1 (34.6)120.2 (34.1)125.9 (35.8)0.257
Atrial fibrillation26 (11.5%)14 (9.3%)12 (15.8%)0.224
Treatment after EE
Angiotensin-converting enzyme inhibitor29 (12.8%)16 (10.7%)13 (17.1%)0.247
Angiotensin II receptor blockers99 (43.8%)54 (36.0%)45 (59.2%)0.001a
Beta-blockers72 (31.9%)44 (29.3%)28 (36.8%)0.32
Calcium channel blockers53 (23.5%)27 (18.0%)26 (34.2%)0.011a
Nitrates21 (9.3%)13 (8.7%)8 (10.5%)0.832
Statins111 (49.1%)66 (44.0%)45 (59.2%)0.043a
Ezetimibe6 (2.7%)3 (2.0%)3 (3.9%)0.673
Fibrates10 (4.4%)5 (3.3%)5 (6.6%)0.476
Omega−3 fatty acids4 (1.8%)3 (2.0%)1 (1.3%)1
Antiplatelet drugs109 (48.2%)67 (44.7%)42 (55.3%)0.172
Anticoagulants drugs17 (7.5%)8 (5.3%)9 (11.8%)0.137
Oral antidiabetic drugs28 (12.4%)13 (8.7%)15 (19.7%)0.030a
Insulin treatment5 (2.2%)2 (1.3%)3 (3.9%)0.338

  • Citation: Vidal-Perez R, Franco-Gutiérrez R, Pérez-Pérez AJ, Franco-Gutiérrez V, Gascón-Vázquez A, López-López A, Testa-Fernández AM, González-Juanatey C. Subclinical carotid atherosclerosis predicts all-cause mortality and cardiovascular events in obese patients with negative exercise echocardiography. World J Cardiol 2019; 11(1): 24-37
  • URL: https://www.wjgnet.com/1949-8462/full/v11/i1/24.htm
  • DOI: https://dx.doi.org/10.4330/wjc.v11.i1.24